Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
A phase 1/2 trial of MCLA-129 in non-small-cell lung cancer and small-cell lung cancer, run by Betta Pharmaceuticals Co., Ltd., now recruiting.
Overview
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors is a phase 1/2 interventional study registered as NCT04930432 by Betta Pharmaceuticals Co., Ltd., with 400 participants planned, started 2021-09-24 and due to reach its primary completion in 2028-04-30. Interventions recorded: MCLA-129. Conditions listed: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina
Shares MCLA-129, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
- TrialStudy of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.
Shares Betta Pharmaceuticals, MCLA-129.
- TrialAdjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Shares Betta Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TreatmentBefotertinib
- TrialSequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- TreatmentIcotinib
- TreatmentEnsartinib